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E D I T O R I A L
Donor infection with multidrug resistant organisms: Should we 
change our approach to perioperative prophylaxis?
Transmission of disease from donor to recipient remains an inevita‐
ble consequence of solid organ transplantation. In fact, the inten‐
tional transmission of viruses such as cytomegalovirus is routine; 
management strategies reduce the negative consequences of these 
transmissions. Unexpected transmission of disease is much less 
common, complicating <1% of organ transplants. Nonetheless, con‐
sequences can be severe with significant recipient morbidity and 
mortality and the potential to reduce public trust in the safety of the 
organ procurement system.
Much of the regulatory attention regarding donor‐derived dis‐
ease has focused on blood borne viruses, particularly—in light of 
the opioid epidemic—hepatitis C virus (HCV). More sensitive test‐
ing methods combined with direct acting antivirals that cure post‐
transplant HCV have reduced the risk and consequence of donor 
transmission of HCV. What then should the transplant community 
prioritize in decreasing the impact of donor disease transmission? 
One emerging and poorly studied area is donor infection with mul‐
tidrug‐resistant organisms (MDRO). The World Health Organization 
cites antibiotic resistance as “one of the biggest threats to global 
health, food, and security” and that “new resistance mechanisms 
are emerging and spreading globally, threatening our ability to treat 
common diseases.”1	According	 to	 the	Centers	 for	Disease	Control	
and Prevention, 2 million infections with MDROs resulting in 23 000 
deaths occur yearly in the United States.2 In some circumstances, no 
reliably effective antibiotics are available to treat these organisms.
The published literature on the impact of donor‐derived infection 
with MDROs is limited, but transmission of infection from donors in‐
fected at various sites (blood, sputum, preservative fluid, peritoneal 
fluid) with significant recipient morbidity has been described.3-5 In a 
large cases series from Italy, 30 recipients were exposed to donors 
infected with carbapenem‐resistant gram negative bacteria. In 14 of 
these 30 recipients, the donor had either bacteremia or infection of 
the transplanted organ. Four of six exposed recipients not promptly 
receiving active antimicrobial therapy developed clinical infection 
or colonization, and one died. Interestingly, the eight recipients ef‐
fectively treated for at least 7 days did not develop donor‐derived 
infection.4
Organs from deceased donors have many of the traditional risk 
factors for infection with MDROs including prolonged hospitaliza‐
tion, receipt of antimicrobials, treatment in an intensive care unit, 
and mechanical ventilation. When culture and sensitivity informa‐
tion is available preprocurement (eg, isolation of multidrug‐resistant 
Acinetobacter from a tracheal aspirate isolated a few days prior to 
lung procurement) tailored antibiotics can be administered to the re‐
cipient, reducing the risk of infection. The more common scenario, 
however, is that hospital cultures (obtained as part of routine care) or 
those performed specifically as part of the donation evaluation pro‐
cess	become	available	after	transplantation.	In	this	issue,	Anesi	and	
colleagues studied whether specific donor characteristics predicted 
donor infection (“active” infection not distinguished from coloniza‐
tion) with MDROs.6 The investigators reviewed deceased donors 
who donated to one of 4 Philadelphia transplant centers and were 
evaluated by the local organ procurement organization (OPO). Time 
to donor isolation of an MDRO was the primary outcome, and donor 
characteristics including antibiotic treatment were used to identify 
risk factors for MDRO infection.
The most important finding was that MDRO infection rates in‐
creased with length of stay with 20% of donors infected by hospital 
day 10. Methicillin‐resistant Staph aureus	(MRSA)	was	the	most	fre‐
quent pathogen, and most infections involved the respiratory tract 
with	only	5	(1%)	bloodstream	infections.	Important	risk	factors	for	
MDRO infection on multivariable analysis included HCV viremia 
(largely	for	MRSA),	dialysis,	 receipt	of	narrow-spectrum	gram	neg‐
ative antibiotics, and asphyxiation (for resistant Enterobacteriaceae). 
Interestingly the T4 protocol (which uses glucocorticoids and ex‐
tensive	 central	 vascular	 access)	 was	 also	 associated	 with	 MRSA	
infection.
How can these findings be used to reduce donor‐derived infec‐
tion?	Although	the	rates	of	MDRO	donor	colonization	are	alarming,	
most of the cultures are from respiratory samples that—although 
they might indicate colonization at other sites—have not been shown 
to require targeted interventions in nonlung recipients, and certainly 
universally broadening antimicrobial prophylaxis is likely to worsen 
the MDRO problem. Rather, these findings may represent an import‐
ant early step toward a targeted approach where a combination of 
factors (eg, prolonged duration of hospitalization, colonization with 
MDRO organisms at multiple sites, prolonged antimicrobial treat‐
ment) may identify donors at a high enough risk of MDRO infection 
to justify enhanced perioperative prophylaxis. Such an approach 
would be complex, would need to account for local differences in 
MDRO ecology, and distinguish between gram positive and gram 
negative MDROs because treatment would differ. Importantly, 
given the risk of creating further resistance, a better understanding 
of recipient outcomes associated with donor MDRO infection is re‐
quired	before	enhanced	prophylaxis	can	be	recommended.	Although	
the	Anesi	 study	 is	 an	excellent	beginning,	 in	 addition	 to	 assessing	
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recipient outcomes, future studies should involve multiple OPOs 
as local differences in resistance patterns and MDROs of greatest 
concern would be expected. It is hoped that research in this area 
will help us make the most informed choice when faced with the 
decision to accept or decline an organ offer from a donor infected 
with an MDRO.
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